PainReform (PRFX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainReform Ltd., a pharmaceutical company, has presented its unaudited condensed financial statements for the first half of 2024, showing a significant decrease in total assets from $9,930,000 at the end of 2023 to $3,107,000 as of June 30, 2024. The report highlights a sharp decline in cash and cash equivalents alongside an increase in total current liabilities, indicating potential financial challenges ahead for the firm.
For further insights into PRFX stock, check out TipRanks’ Stock Analysis page.